SeaStar Medical HoldingNASDAQ: ICU

DENVER, June 10, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) announces that three new members have joined its Board of Directors. Two new directors, Jennifer A. Baird and Bernadette N. Vincent, were elected at the Company's 2024 Annual Meeting of Stockholders held on June 4, and John Neuman was appointed to the Board on June 5. Former directors Bruce Rodgers and Richard Russell did not stand for reelection at the 2024 Annual Meeting, and Andres Lobo announced his retirement from Dow Chemical, resulting in his departure from the SeaStar Medical Board.

DENVER, June 07, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the publication of a peer-reviewed article in Nature Scientific Reports that describes the mechanism of action of the Company's Selective Cytopheretic Device (SCD) in the immunomodulation of excessive inflammation. “ Immunomodulatory effects of a cell progressing device to ameliorate dysregulated hyperinflammatory disease states ,” authored by Angela J. Westover, H. David Humes and Christopher J. Pino, (2024) 14:12747, investigated the SCD as an evolving approach to treating organ dysfunction arising from hyperinflammation and the cytokine storm by processing leukocytes in an extracorporeal circuit.

DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Eric Schlorff, CEO, will hold a fireside chat at the Virtual Emerging Growth Conference on Wednesday, June 12 at 12:35 p.m. Eastern time (9:35 a.m. Pacific time).

DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the Company's 25-for-1 reverse stock split, which will become effective at June 7, 2024 at 5:00 PM EDT. The Company's common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market (Nasdaq) effective with the open of the market on June 10, 2024. SeaStar Medical's stock will continue to trade under the ticker symbol “ICU.”

SeaStar Medical Holding (NASDAQ: ICU) stock price has done well this year even as the company continued diluting its shareholders. The stock is about to hit $1, meaning that it has surged by more than 177% from the lowest point in December and by 495% from its 2023 low.

Shares of SeaStar Medical Holding Corp. ICU, +70.05% rocketed 45.3% on heavy volume in premarket trading Thursday, to take them back above the $1 mark for the first time in five months. Trading volume spiked to 21.4 million shares ahead of the open, to already match the full-day average.

DENVER, Aug. 22, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will hold a business update conference call today at 4:00 p.m. Eastern time (1:00 p.m. Pacific time). During the call, management will provide a clinical and regulatory update and review the Company's value proposition, including the commercial opportunity.

SeaStar Medical (NASDAQ: ICU ) stock is on the rise Thursday as the medical technology company's shares see plenty of activity today. During the early trading hours, some 6 million shares of ICU stock changed hands.

SeaStar Medical (NASDAQ: ICU ) stock is falling on Wednesday after the medical technology company got an update from the FDA. What's hitting ICU stock is the FDA not approving its Humanitarian Device Exemption (HDE) application for pediatric Selective Cytopheretic Device ( SCD ).